Select Page
Fixing the antibiotic innovation pipeline
Online discussion hosted by the MEP Interest Group on AMR

17 November 2020

11:00-12:00 CET

online

The third of three online discussions in the run up to European Antibiotic Awareness Day hosted by the MEP Interest Group on AMR to raise awareness of the need for action, and find evidence-informed policy solutions to this urgent threat to human, animal and environmental health.

Take part in the debate and discuss what can can be done to boost actions to tackle AMR at EU level.

#MEPvsAMR 

The current antibiotic innovation pipeline is broken. The last antibiotic class that was successfully introduced as a treatment was discovered back in 1987. As resistance grows, it is key to develop new tools and invest in research into new antibiotics and  alternatives to avoid further spread of diseases and increased resistance. 

Earlier this year, the pharmaceutical industry launched a US$1bn AMR Action Fund that aims to bring two to four novel antibiotics to the market by 2030. Still, many details of the Fund need to be disclosed and this initiative does not diminish the crucial need for public investment across the entire chain to address the market failures in antibiotic research and innovation. 

Moreover, the awareness of the relationship between the use of antimicrobials and the development and spread of AMR is still low. The misuse and overuse of antibiotics has to end, alternative treatments and stewardships for healthcare professionals need to be offered and a focus should also be put on better access to rapid and affordable diagnostic tools

Join us to discuss 

How can the development of new needs-driven models to finance and stimulate antibiotic R&D be supported?

How can the EU promote R&D models that ensure responsible use of and equitable and affordable access to antibiotics?

How can the Pharmaceutical Strategy be a game changer and contribute to fixing the antibiotic innovation pipeline?

How can the EU raise more awareness on AMR and how can we prevent the misuse and overuse of antibiotics on the ground?

Hosted by

Tiemo Wölken MEP

Vice-Chair of the MEP Interest Group on Antimicrobial Resistance

S&D, Germany

 

Panelists

Helle Aagaard

Deputy Director

ReAct Europe

Tim Jinks

Head of the Drug-Resistant Infections Programme

The Wellcome Trust

Moderated by

Marc Gitzinger

Vice-President

BEAM Alliance

 

Willo Brock

Senior Vice-President of External Affairs

TB Alliance

 

Zoltán Massay-Kosubek

Policy Manager

European Public Health Alliance

 

 

Jean-Yves Stenuick

Pharmaceuticals Policy & Projects Officer

Health Care Without Harm (HCWH) Europe

 

Join the MEP Interest Group on AMR also for:

AMR in the environment: From monitoring to action

13 November 2020

11:00-12:00 CET

Tackling the dependence of EU food systems on antimicrobials

16 November 2020

11:00-12:00 CET

Contact

Zoltán Massay-Kosubek

Policy Manager

European Public Health Alliance
zoltan@epha.org

Jean-Yves Stenuick

Pharmaceuticals Policy & Projects Officer

Health Care Without Harm (HCWH) Europe

jean-yves.stenuick@hcwh.org

 

HCWH Europe gratefully acknowledges the financial support of the European Commission (EC)’s LIFE programme. HCWH Europe is solely responsible for the content of this project and related materials. The views expressed do not reflect the official views of the EC.